Clinical Trials Logo

Ear Diseases clinical trials

View clinical trials related to Ear Diseases.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03852329 Terminated - Otologic Disease Clinical Trials

Feasibility of Stereotactic Image Guidance on the Lateral Skull Base

LSBN
Start date: January 1, 2020
Phase: N/A
Study type: Interventional

A clinical trial to asses the accuracy, usefulness and usability of a stereotactic image-guidance system during lateral skull base surgery.

NCT ID: NCT02189798 Terminated - Hearing Loss Clinical Trials

Implantation of the HiRes90K™ Advantage Cochlear Implant With HiFocus™ Mid-Scala and Development of a Combined Electric and Acoustic Stimulation Technology in Adults With Partial Deafness

Start date: October 21, 2014
Phase: N/A
Study type: Interventional

The purpose of this feasibility study is to evaluate whether low-frequency acoustic hearing sensitivity can be preserved in newly implanted adults with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss) using the HiResolution™ 90K™ Advantage cochlear implant with the HiFocus™ Mid-Scala electrode to support the development of electro-acoustic stimulation technology (EAS).

NCT ID: NCT01959152 Terminated - Hearing Loss Clinical Trials

Evaluation of Hearing Preservation in Adults With Partial Low-Frequency Hearing Implanted With the HiFocus™ Mid-Scala Electrode

Start date: October 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the feasibility of preserving low-frequency acoustic hearing in adults with a moderate degree of hearing loss in the low frequencies and severe-to-profound hearing loss in the mid-to-high frequencies who are implanted with the HiRes™ 90K Advantage implant with HiFocus™ Mid-Scala electrode.

NCT ID: NCT01526174 Terminated - Clinical trials for Autoimmune Inner Ear Disease

Intratympanic Injection for Autoimmune Inner Ear Disease

AIED
Start date: March 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The investigators plan to conduct an open-label intratympanic injection proof-of-concept trial of golimumab, a TNF-alpha inhibitor, assessing for hearing loss progression in patients with autoimmune inner ear disease (AIED). This specific aim will be achieved using a two-arm approach. First, the investigators propose to dose 3 individual subjects with a single intratympanic injection of golimumab and follow each for 30 days, closely examining them for adverse events. If there are no serious adverse events, with FDA approval, the investigators propose to dose 14 subjects, each with 4 intratympanic injections of golimumab.